Integrated Annual Report for FY 2024-25
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India has filed its Integrated Annual Report for FY 2024-25 along with the notice of its 34th Annual General Meeting scheduled for August 7, 2025. The company reported revenue of ₹44,816 Mn (down 1% YoY), with EBITDA improving 10% to ₹9,452 Mn and Profit After Tax rising 24% to ₹5,015 Mn. Finished Dosages now contribute 77% of revenue (up from 65%), while North America accounts for 77% of total revenue. Key strategic moves during the year include the acquisition of Switzerland-based Senn Chemicals AG and the launch of Ascelis Peptides, marking entry into the peptide therapeutics space. The company also invested ₹2,377 Mn in R&D and ₹5,700 Mn in capex, while achieving EcoVadis Gold rating and SBTi validation for net-zero targets.
The annual report is a routine regulatory filing with no immediate impact on share price, though it highlights margin expansion, debt reduction (net debt down to ₹7,061 Mn), and growth investments in peptides and complex generics that could support future earnings. Investors should watch the upcoming AGM for any management commentary or guidance.